Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism

Xenobiotica

Volumn 42, Issue 12, 2012, Pages 1248-1254

  He, X ^a,b   Mo, L ^c   Li, Z Y ^b   Tan, Z R ^a   Chen, Y ^a   Ouyang, D S ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Third Hospital of Changsha   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Curcumin; Multidrug resistance 1 (MDR1 ABCB1); P glycoprotein; Pharmacokinetics; Polymorphism; Talinolol

Indexed keywords

CURCUMIN; MULTIDRUG RESISTANCE PROTEIN 1; TALINOLOL;

ALLELE; ARTICLE; CHINESE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MICROCAPSULE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; CURCUMIN; GENOTYPE; HUMANS; MALE; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPANOLAMINES; TIME FACTORS; YOUNG ADULT;

EID: 84868628425     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.697590     Document Type: Article

References (36)

1. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH. (2008). Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics 18:299-305.
2. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. (2007). Curcumin: the Indian solid gold. Adv Exp Med Biol 595:1-75.
3. Bar-Sela G, Epelbaum R, Schaffer M. (2010). Curcumin as an anti-cancer agent: Review of the gap between basic and clinical applications. Curr Med Chem 17:190-197.
4. Bartels AL, de Klerk OL, Kortekaas R, de Vries JJ, Leenders KL. (2010). 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Curr Top Med Chem 10:1775-1784.
5. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, Chollet P. (2010). Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9:8-14.
6. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, Kakarala M, Carpenter PM, McLaren C, Meyskens FL Jr, Brenner DE. (2011). Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 4:354-364.
7. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174.
8. Cho YA, Lee W, Choi JS. (2012). Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin. Pharmazie 67:124-130.
9. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH. (2008). Curcumin downregulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF κ B pathway. Cancer Lett 259:111-118.
10. Constantinides PP, Wasan KM. (2007). Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci 96:235-248.
11. Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG. (2011). Safety assessment of a solid lipid curcumin particle preparation: Acute and subchronic toxicity studies. Food Chem Toxicol 49:1834-1842.
12. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491-4499.
13. Epstein J, Sanderson IR, Macdonald TT. (2010). Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr 103:1545-1557.
14. Goel A, Aggarwal BB. (2010). Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 62:919-930.
15. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S. (2006). Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34:69-74.
16. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
17. Hou XL, Takahashi K, Tanaka K, Tougou K, Qiu F, Komatsu K, Takahashi K, Azuma J. (2008). Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite ways. Int J Pharm 358:224-229.
18. Juan H, Terhaag B, Cong Z, Bi-Kui Z, Rong-Hua Z, Feng W, Fen-Li S, Juan S, Jing T, Wen-Xing P. (2007). Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 63:663-668.
19. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
20. Limtrakul P, Anuchapreeda S, Buddhasukh D. (2004). Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4:13.
21. Liu S, Beringer PM, Hidayat L, Rao AP, Louie S, Burckart GJ, Shapiro B. (2008). Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. J Clin Pharmacol 48:957-965.
22. Menon VP, Sudheer AR. (2007). Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595:105-125.
23. Oswald S, Terhaag B, Siegmund W. (2011). In vivo probes of drug transport: Commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans. Handb Exp Pharmacol 201:403-447.
24. Qian W, Homma M, Itagaki F, Tachikawa H, Kawanishi Y, Mizukami K, Asada T, Inomata S, Honda K, Ohkohchi N, Kohda Y. (2006). MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull 29:2446-2450.
25. Raju TN, Kumar CS, Kanth VR, Ramana BV, Reddy PU, Suryanarayana P, Reddy GB. (2006). Cumulative antioxidant defense against oxidative challenge in galactose-induced cataractogenesis in Wistar rats. Indian J Exp Biol 44:733-739.
26. Romiti N, Tongiani R, Cervelli F, Chieli E. (1998). Effects of curcumin on P-glycoprotein in primary cultures of rat hepatocytes. Life Sci 62:2349-2358.
27. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. (2007). Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669-678.
28. Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I. (2002). The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572-583.
29. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P. (1998). P-glycoprotein transporters and the gastrointestinal tract: Evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24.
30. Suryanarayana P, Krishnaswamy K, Reddy GB. (2003). Effect of curcumin on galactose-induced cataractogenesis in rats. Mol Vis 9:223-230.
31. Tang XQ, Bi H, Feng JQ, Cao JG. (2005). Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/ VCR. Acta Pharmacol Sin 26:1009-1016.
32. Trausch B, Oertel R, Richter K, Gramatte T. (1995). Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 16:403-414.
33. Verschoyle RD, Steward WP, Gescher AJ. (2007). Putative cancer chemopreventive agents of dietary origin-how safe are they? Nutr Cancer 59:152-162.
34. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: Concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514-522.
35. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, Jung HR, Cho JY, Yu KS, Jang IJ, Shin SG. (2004). A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 76:418-427.
36. Zhang W, Tan TM, Lim LY. (2007). Impact of curcumin-induced changes in P-glycoprotein and CYP3A expression on the pharmacokinetics of peroral celiprolol and midazolam in rats. Drug Metab Dispos 35:110-115.